2. GPCR/G Protein Apoptosis
  3. Platelet-activating Factor Receptor (PAFR) Apoptosis
  4. Ginkgolide B

Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.

For research use only. We do not sell to patients.

Ginkgolide B Chemical Structure

Ginkgolide B Chemical Structure

CAS No. : 15291-77-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Ginkgolide B:

Ginkgolide B Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments[1][2].

In Vitro

Ginkgolide B (BN-52021; 30-150 μM; 24 h) inhibits the up-regulation of VCAM-1 and E-selectin protein expression induced by TNF-α (10 ng/mL)[1].
Ginkgolide B (30-150 μM; 24, 48 h) increases CYP3A4 mRNA and MDR1 expression[1].
Ginkgolide B (30-150 μM; pretreated for 24 h) reduces Staurosporine-induced (500 nM; 6 h) apoptosis compared with the positive controls, which exhibited marked apoptosis compared with negative controls. Ginkgolide B does not affect Doxorubicin (5 μM; 24 h) induced apoptosis[1].
Ginkgolide B regulates PXR activity and does not affect PXR expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ginkgolide B Related Antibodies

Western Blot Analysis[1]

Cell Line: HUVECs
Concentration: 30, 60, 150 μM
Incubation Time: 24 h
Result: Inhibited the up-regulation of VCAM-1 and E-selectin protein expression induced by TNF-α.

RT-PCR[1]

Cell Line: HUVECs
Concentration: 30, 60, 150 μM
Incubation Time: 24, 48 h
Result: Increased CYP3A4 mRNA and MDR1 expression after 24 h, and this effect was dose-dependent after 48 h.
In Vivo

Ginkgolide B (BN-52021; 20 mg/kg; Intraperitoneally; immediately and 6 hours after ischemia, and thereafter once daily; 14 days) decreases the neurological deficit score[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male clean healthy Sprague-Dawley rats, weighing 250-280 g and aged 8 weeks[2]
Dosage: 20 mg/kg
Administration: Intraperitoneally; immediately and 6 hours after ischemia, and thereafter once daily; 14 days
Result: Decreased the neurological deficit score, increased the proportion of nestin-, neuron-specific enolase- and glial fibrillary acid protein-positive cells.
Caused down-regulation of NSE protein at day 14.
Molecular Weight

424.40

Formula

C20H24O10
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1C(C2([C@H]3O)[C@](OC3=O)([H])O4)([C@@](O5)([H])C[C@H]2C(C)(C)C)C4(C5=O)[C@@](O)([C@@H]6C)[C@@]1([H])OC6=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (235.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3563 mL 11.7813 mL 23.5627 mL
5 mM 0.4713 mL 2.3563 mL 4.7125 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 5 mg/mL (11.78 mM); Suspended solution; Need ultrasonic and warming and heat to 44°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.96%

SDS (393 KB)

COA (256 KB) HNMR (291 KB) RP-HPLC (259 KB) MS (68 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3563 mL 11.7813 mL 23.5627 mL 58.9067 mL
5 mM 0.4713 mL 2.3563 mL 4.7125 mL 11.7813 mL
10 mM 0.2356 mL 1.1781 mL 2.3563 mL 5.8907 mL
15 mM 0.1571 mL 0.7854 mL 1.5708 mL 3.9271 mL
20 mM 0.1178 mL 0.5891 mL 1.1781 mL 2.9453 mL
25 mM 0.0943 mL 0.4713 mL 0.9425 mL 2.3563 mL
30 mM 0.0785 mL 0.3927 mL 0.7854 mL 1.9636 mL
40 mM 0.0589 mL 0.2945 mL 0.5891 mL 1.4727 mL
50 mM 0.0471 mL 0.2356 mL 0.4713 mL 1.1781 mL
60 mM 0.0393 mL 0.1964 mL 0.3927 mL 0.9818 mL
80 mM 0.0295 mL 0.1473 mL 0.2945 mL 0.7363 mL
100 mM 0.0236 mL 0.1178 mL 0.2356 mL 0.5891 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ginkgolide B Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ginkgolide B15291-77-7BN-52021BN52021BN 52021Platelet-activating Factor Receptor (PAFR)Apoptosisterpene lactoneendothelial cellsPXRbrain-blood barrieranti-oxidantanti-inflammatoryanti-tumorneuroprotectiveischemiaimpairmentInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ginkgolide B
Cat. No.:
HY-N0784
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.